Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth

JB Pharma completes 1 year of its identity launch

Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23

Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr

The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023

Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses

Healthcare Global Enterprises revenue up 19%

Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations

Syngene Q3FY23 revenue reaches Rs. 803 Cr; PAT reaches Rs. 110 Cr

The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn

Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%

Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company